Scott N Boyle sold $3,651 of CCCC
Chief Business Officer at C4 Therapeutics, Inc.. 1,159 shares at an average of $3.15, traded Feb 14, 2025, filed Feb 18, 2025.
Score components
- +15RoleOfficer
- 0Trade size$4k at market
- 0Share of holdings soldSold 1.0% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001662579-25-000019, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 13, 2025 | FTax withholding Common Stock10b5-1 | -1,735 | $3.20 | $5,552 | 54,832 | Feb 18, 2025 |
| Feb 14, 2025 | AGrant or award Common Stock10b5-1 | +56,500 | $0.00 | $0 | 111,332 | Feb 18, 2025 |
| Feb 14, 2025 | SOpen-market sale Common Stock10b5-1 | -490 | $3.15 | $1,544 | 110,842 | Feb 18, 2025 |
| Feb 14, 2025 | FTax withholding Common Stock10b5-1 | -2,368 | $3.18 | $7,530 | 108,474 | Feb 18, 2025 |
| Feb 18, 2025 | SOpen-market sale Common Stock10b5-1 | -669 | $3.15 | $2,107 | 107,805 | Feb 18, 2025 |
| Feb 14, 2025 | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +84,700 | $0.00 | $0 | 84,700 | Feb 18, 2025 |
Related signals
Other insiders at C4 Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | CCCCsell C4 Therapeutics, Inc. | Leonard Reyno Chief Medical Officer | $22k 10,000 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.